Clinical Trials Washington DC
Before the U.S. Food and Drug Administration (FDA) can approve a new drug or treatment it must be shown to be both safe and effective. Companies use clinical trials to collect pharmaceutical information to prove the effectiveness of their drug to the FDA.
Below are the on-going clinical trials being conducted in our office. Please contact us at the office or at the form on the right for more information about enrolling in one of our trials.
| Protocol Title:
|
Randomized Trial to Prevent Vascular Events in HIV
REPRIEVE (A5332) |
| Protocol Title:
|
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection
GS-US-412-2055 Click to Download Card About PrEP Clinical Trial Eligibility |
| Protocol Title: | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects
GS-US-292-1823 |
| Protocol Title: | A prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate whether EGRIFTA® (tesamorelin for injection), 2 mg once daily SC, increases the risk of development orprogression of diabetic retinopathy when administered to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes
EMR200147-501 |
| Protocol Title: | A phase 4, observational, multicenter, 10-year prospective cohort safety study comparing subjects with HIV-associated abdominal lipohypertrophy exposed to EGRIFTA® (tesamorelin for injection) to a similar group of subjects not exposed to EGRIFTA®
EMR200147-500 |
Patients are carefully monitored; frequent medical exams and tests are performed to assure their safety. These trials can be an avenue for many to receive not just experimental medications but also much needed medications already approved and on the market currently.
The duration of the clinical trial will vary from course to course and often will include patient care, laboratory testing and medications free of charge to the enrollees.
Our practice is involved with new and exciting protocols. A protocol is a written plan detailing exactly how the trial will be conducted, what information will be gathered and what the researcher hopes to learn.
For additional information on our current clinical trials, please contact Kenneth Granville at 202-822-6311 ext. 103 or on the contact form on this page.
If you are interested in learning about our previous, closed clinical trials click here.